Biomarkers of Drug Safety: Discovery
and Regulatory Aspects

 

National Capital Area Chapter

Society of Toxicology

Fall Symposium

November 6, 2007

Lister Hill Auditorium

National Library of Medicine

Bethesda, MD

 

Program

 

8:30 a.m.                    Registration and Continental Breakfast

 

9:00 a.m.                    Welcome/Opening Remarks

                                    Gary Burin, Ph.D.

                                    President, NCAC-SOT

 

                                    Donna Mendrick, Ph.D.

Vice-President, NCAC-SOT and Program Chair

 

9:10 a.m.                    Computational Framework to Predict Toxicity and Prioritize Testing of Environmental Chemicals

Thomas B. Knudsen, Ph.D.

Developmental Systems Biologist (title 42)

National Center for Computational Toxicology

Office of Research & Development
U.S. Environmental Protection Agency
Research Triangle Park, NC

 

10:00 a.m.                  Experience with a Biomarker Consortium

William Mattes, Ph.D., D.A.B.T.

                                    Director of Toxicology

                                    The Critical Path Institute

                                    Rockville, MD

 

10:50 a.m.                  Break

 

11:10 a.m.                  A Year of Working through a Biomarker Qualification Pilot Process at the FDA

Federico Goodsaid, Ph.D.

                                    Genomics Group

                                    Office of Clinical Pharmacology

                                    Office of Translational Science

                                    Center for Drug Evaluation and Research. U.S. Food and Drug Administration

                                    Silver Spring, MD

 

12:00 p.m.                  Lunch (Box lunch and beverage included in registration fee)

 

1:00 p.m.                    Bridging Exploratory Biomarkers into Drug Development

Joseph Sina, Ph.D.

                                    Senior Scientific Director, Systems Toxicology

                                    Department of Safety Assessment

                                    Mereck & Co., Inc.

                                    West Point, PA

 

1:50 p.m.                    Break

 

2:10 p.m.                    Thinking About How a Preclinical Program Can Translate into the Clinic

Jerry M. Collins, Ph.D.

                                    Associate Director for Developmental Therapeutics

                                    Division of Cancer Treatment and Diagnosis, NCI, NIH

                                    Bethesda, MD

 

3:00 p.m.                    Monitoring Genetic Toxicity Indicators in Clinical Trials: Pros and Cons

David Jacobson-Kram, Ph.D., D.A.B.T.

                                    Associate Director for Pharmacology and Toxicology

                                    Office of New Drugs

                                    Center for Drug Evaluation and Research

                                    Silver Spring, MD 20993

 

3:50 p.m.                    Closing Remarks

                                    Donna Mendrick, Ph.D.

                                    Vice-President, NCAC-SOT and Program Chair

 

4:00 p.m.                    Meeting Adjourned

 

 

SPEAKER SLIDE PRESENTATIONS (In Adobe Acrobat®)